热门资讯> 正文

Sagimet Biosciences以1.75亿美元的股票发行价格上涨30%

2026-04-27 19:35

Clinical-stage biopharmaceutical company Sagimet Biosciences (SGMT) stock price jumped about 30% on Monday pre-market hours as the company priced an underwritten offering of ~29M shares at $6.00 per share.
The gross proceeds of $175M. Net proceeds combined with existing capital will be used to fund a Phase 3 trial for denifanstat in acne, advance TVB-3567 and a topical FASN inhibitor, and cover general corporate expenses. The company expects this funding to sustain its acne program operations and support the Phase 3 trial readout through 2028.
The offering is expected to close on or about April 28, 2026.

More on Sagimet Biosciences

Sagimet Biosciences Inc. (SGMT) Presents at Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium - Slideshow
Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Sagimet Biosciences Inc. (SGMT) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Sagimet Biosciences GAAP EPS of -$0.29
Sagimet a new buy at Guggenheim on promise of MASH, acne asset

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。